

Prostate Cancer (Oncology) - Drugs in Development, 2021

https://marketpublishers.com/r/P42763C9F29AEN.html

Date: November 2021

Pages: 4131

Price: US\$ 2,500.00 (Single User License)

ID: P42763C9F29AEN

Abstracts

Prostate Cancer (Oncology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Drugs In Development, 2021, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy, and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued



projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 28, 193, 177, 2, 16, 333, 70 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 14, 19, 2, 69 and 24 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on



mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction

Global Markets Direct Report Coverage

Prostate Cancer - Overview

Prostate Cancer - Therapeutics Development

Prostate Cancer - Therapeutics Assessment

Prostate Cancer - Companies Involved in Therapeutics Development

Prostate Cancer - Drug Profiles

Prostate Cancer - Dormant Projects

Prostate Cancer - Discontinued Products

Prostate Cancer - Product Development Milestones

Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Prostate Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Prostate Cancer - Pipeline by 3D Medicines Inc, 2021

Prostate Cancer - Pipeline by 4D Pharma Plc, 2021

Prostate Cancer - Pipeline by 4SC AG, 2021

Prostate Cancer - Pipeline by Aavocyte Inc, 2021

Prostate Cancer - Pipeline by AB Science SA, 2021

Prostate Cancer - Pipeline by Abbisko Therapeutics Co Ltd, 2021

Prostate Cancer - Pipeline by AbbVie Inc, 2021

Prostate Cancer - Pipeline by Abion Inc, 2021

Prostate Cancer - Pipeline by Accutar Biotechnology Inc, 2021

Prostate Cancer - Pipeline by Acrotech Biopharma LLC, 2021

Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, 2021

Prostate Cancer - Pipeline by Actuate Therapeutics Inc, 2021

Prostate Cancer - Pipeline by ADC Therapeutics SA, 2021

Prostate Cancer - Pipeline by Adicet Bio Inc, 2021

Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, 2021

Prostate Cancer - Pipeline by Advaxis Inc, 2021

Prostate Cancer - Pipeline by Advenchen Laboratories LLC, 2021

Prostate Cancer - Pipeline by Adze Biotechnology Inc, 2021

Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, 2021

Prostate Cancer - Pipeline by Affina Biotechnologies Inc, 2021

Prostate Cancer - Pipeline by Agenus Inc, 2021

Prostate Cancer - Pipeline by Alkido Pharma Inc, 2021

Prostate Cancer - Pipeline by AIM ImmunoTech Inc, 2021

Prostate Cancer - Pipeline by Akshaya Bio Inc, 2021

Prostate Cancer - Pipeline by Alessa Therapeutics Inc, 2021

Prostate Cancer - Pipeline by Alla Chem LLC, 2021



Prostate Cancer - Pipeline by Allife Medical Science and Technology Co Ltd, 2021

Prostate Cancer - Pipeline by Alligator Bioscience AB, 2021

Prostate Cancer - Pipeline by Almac Discovery Ltd, 2021

Prostate Cancer - Pipeline by AlphaMab Co Ltd, 2021

Prostate Cancer - Pipeline by Alphamab Oncology, 2021

Prostate Cancer - Pipeline by ALRISE Biosystems GmbH, 2021

Prostate Cancer - Pipeline by Altay Therapeutics Inc, 2021

Prostate Cancer - Pipeline by Ambrx Biopharma Inc, 2021

Prostate Cancer - Pipeline by American Gene Technologies International Inc, 2021

Prostate Cancer - Pipeline by Amgen Inc, 2021

Prostate Cancer - Pipeline by Amphivena Therapeutics Inc., 2021

Prostate Cancer - Pipeline by Anastasis Biotec Ltd, 2021

Prostate Cancer - Pipeline by Anavex Life Sciences Corp, 2021

Prostate Cancer - Pipeline by Andes Biotechnologies, 2021

Prostate Cancer - Pipeline by Anew Oncology Inc, 2021

Prostate Cancer - Pipeline by AnGes Inc, 2021

Prostate Cancer - Pipeline by Anhorn Medicines Co Ltd, 2021

Prostate Cancer - Pipeline by Antapodia Therapeutics Inc, 2021

Prostate Cancer - Pipeline by Antares Pharma Inc, 2021

Prostate Cancer - Pipeline by Antev Ltd, 2021

Prostate Cancer - Pipeline by AntiCancer Inc, 2021

Prostate Cancer - Pipeline by Antikor Biopharma Ltd, 2021

Prostate Cancer - Pipeline by Apcure SAS, 2021

Prostate Cancer - Pipeline by Apexian Pharmaceuticals Inc, 2021

Prostate Cancer - Pipeline by Aphios Corp, 2021

Prostate Cancer - Pipeline by Apidel SA, 2021

Prostate Cancer - Pipeline by APIM Therapeutics AS, 2021

Prostate Cancer - Pipeline by Aprilbio Co Ltd, 2021

Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, 2021

Prostate Cancer - Pipeline by Aqualung Therapeutics Corp, 2021

Prostate Cancer - Pipeline by IC-MedTech Inc, 2021

Prostate Cancer - Pipeline by Idience Co Ltd, 2021

Prostate Cancer - Pipeline by IGM Biosciences Inc, 2021

Prostate Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, 2021

Prostate Cancer - Pipeline by ImCheck Therapeutics SAS, 2021

Prostate Cancer - Pipeline by Immune Biosolutions Inc, 2021

Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc, 2021

Prostate Cancer - Pipeline by Immunic Inc, 2021

Prostate Cancer - Pipeline by ImmunityBio Inc, 2021



Prostate Cancer - Pipeline by Immunogenesis Inc, 2021

Prostate Cancer - Pipeline by ImmunoRestoration Inc, 2021

Prostate Cancer - Pipeline by ImmunSYS Inc, 2021

Prostate Cancer - Pipeline by ImmuSmol SAS, 2021

Prostate Cancer - Pipeline by IMPACT Therapeutics Inc, 2021

Prostate Cancer - Pipeline by Incyte Corp, 2021

Prostate Cancer - Pipeline by Inmune Bio Inc, 2021



List Of Figures

LIST OF FIGURES

Number of Products under Development for Prostate Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021



I would like to order

Product name: Prostate Cancer (Oncology) - Drugs in Development, 2021

Product link: https://marketpublishers.com/r/P42763C9F29AEN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P42763C9F29AEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970